How an Unproven Alzheimer ’s Drug Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen ’s Aduhelm, or aducanumab.
Source: NYT Health - Category: Consumer Health News Authors: Pam Belluck, Sheila Kaplan and Rebecca Robbins Tags: Aduhelm (Drug) Alzheimer ' s Disease Food and Drug Administration Drugs (Pharmaceuticals) Labeling and Labels (Product) Clinical Trials Elderly Science and Technology Regulation and Deregulation of Industry Research Brain Biogen Source Type: news
More News: Alzheimer's | Brain | Clinical Trials | Food and Drug Administration (FDA) | Health | Neurology | Science